Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine (Published September 20, 2010)
mTOR and ERK signaling was inhibited in proliferating endothelial cells and was more pronounced at the RD with the larger amount of ridaforolimus.
10 of 29 evaluable patients had stable disease for => 6 months
Conclusion Good tolerability, feasibility of prolonged treatment, antitumor activity, and favorable pharmacologic profile support further investigation of this combination.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.